Carter Donald B
CNS Therapeutics, Pfizer Corporation, Kalamazoo, MI, USA.
Subcell Biochem. 2005;38:255-72. doi: 10.1007/0-387-23226-5_13.
Brain plaque deposition in the form of amyloid-beta (Abeta) peptide is a pathological hallmark of Alzheimer's disease (AD). Apolipoprotein E (ApoE) is thought to be involved in plaque formation. Individuals afflicted with AD carrying the ApoE4 isoform have shown a greater number of Abeta plaques when compared to ApoE3 carriers, and inheritance of an ApoE4 allele increases the risk of AD when compared to ApoE2 and ApoE3 carriers. The role of ApoE in the pathogenesis of AD is not well understood but a hypothesis gaining widespread support is that ApoE is involved in deposition or clearance of Abeta by direct protein-to-protein interaction. We have established that various human Abeta conformations apparent during spontaneous aggregation confer differing degrees of binding to the three ApoE isoforms. When associated with lipid, ApoE4 bound preferentially to an intermediate aggregated form of Abeta and had higher avidity than did ApoE2 or ApoE3.
以β-淀粉样蛋白(Aβ)肽形式存在的脑斑块沉积是阿尔茨海默病(AD)的病理标志。载脂蛋白E(ApoE)被认为与斑块形成有关。与携带ApoE3的个体相比,携带ApoE4异构体的AD患者显示出更多的Aβ斑块,并且与携带ApoE2和ApoE3的个体相比,ApoE4等位基因的遗传增加了患AD的风险。ApoE在AD发病机制中的作用尚未完全了解,但一个得到广泛支持的假说是,ApoE通过直接的蛋白质-蛋白质相互作用参与Aβ的沉积或清除。我们已经确定,在自发聚集过程中出现的各种人类Aβ构象与三种ApoE异构体具有不同程度的结合。与脂质结合时,ApoE4优先结合Aβ的中间聚集形式,并且比ApoE2或ApoE3具有更高的亲和力。